Alzheimer’s disease has been one of the toughest disorders for drugmakers to tackle, with multiple trial failures year after year. Companies have exhausted resources as they examined different pathways in what have mostly been futile attempts to develop a therapeutic to halt or delay the onset of this devastating neurodegenerative disease.
Why The Next Biotech Boom Could be Sparked by New Therapies for Neurological Disorders Several Maryland Biotech Firms Are Blazing New Trails in Gene Therapy, Drugs and Diagnostics for Neurological [….]
Germantown, MD-based Neuraly & Theraly Fibrosis Advance Clinical Parkinson’s and Alzheimer’s Candidates with $137.1M in Series B Financing Raised by Parent Company D&D Pharmatech
Neuraly Theraly Fibrosis raise $137.1M in Series B from Korean Parent Company DD Pharmatech
3 Promising Maryland Biotechs that are Targeting Neurological Disorders BrainScope, AgeneBio and Neuraly February 13, 2019 Neurological disorders are diseases of the central nervous system such as Alzheimer’s and Parkinson’s. [….]